» Articles » PMID: 19363497

Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer

Abstract

Many studies have shown that primary prostate cancers are multifocal and are composed of multiple genetically distinct cancer cell clones. Whether or not multiclonal primary prostate cancers typically give rise to multiclonal or monoclonal prostate cancer metastases is largely unknown, although studies at single chromosomal loci are consistent with the latter case. Here we show through a high-resolution genome-wide single nucleotide polymorphism and copy number survey that most, if not all, metastatic prostate cancers have monoclonal origins and maintain a unique signature copy number pattern of the parent cancer cell while also accumulating a variable number of separate subclonally sustained changes. We find no relationship between anatomic site of metastasis and genomic copy number change pattern. Taken together with past animal and cytogenetic studies of metastasis and recent single-locus genetic data in prostate and other metastatic cancers, these data indicate that despite common genomic heterogeneity in primary cancers, most metastatic cancers arise from a single precursor cancer cell. This study establishes that genomic archeology of multiple anatomically separate metastatic cancers in individuals can be used to define the salient genomic features of a parent cancer clone of proven lethal metastatic phenotype.

Citing Articles

Shifting tides: A survey analysis of urologists' evolving attitudes toward focal therapy for prostate cancer.

Koehler J, Lazarovich A, Tayebi S, Viswanath V, George A, Hsu W Indian J Urol. 2025; 41(1):59-65.

PMID: 39886635 PMC: 11778692. DOI: 10.4103/iju.iju_239_24.


The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

Pedrani M, Barizzi J, Salfi G, Nepote A, Testi I, Merler S Int J Mol Sci. 2025; 26(1.

PMID: 39796175 PMC: 11719667. DOI: 10.3390/ijms26010318.


DICE: fast and accurate distance-based reconstruction of single-cell copy number phylogenies.

Weiner S, Bansal M Life Sci Alliance. 2024; 8(3).

PMID: 39667913 PMC: 11638338. DOI: 10.26508/lsa.202402923.


High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial.

Hommerding O, Bernhardt M, Kreft T, Scherping A, Abbas M, Baretton G Virchows Arch. 2024; .

PMID: 39653828 DOI: 10.1007/s00428-024-03999-y.


Spatial transcriptomics identifies RBM39 as a gene a Gleason score progression in prostate cancer.

Quan Y, Wang M, Zhang H, Lu D, Ping H iScience. 2024; 27(12):111351.

PMID: 39650727 PMC: 11625293. DOI: 10.1016/j.isci.2024.111351.


References
1.
Cheng L, Bostwick D, Li G, Wang Q, Hu N, Vortmeyer A . Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer. 1999; 85(9):2017-22. DOI: 10.1002/(sici)1097-0142(19990501)85:9<2017::aid-cncr20>3.0.co;2-v. View

2.
Eastham J, Stapleton A, Gousse A, Timme T, Yang G, Slawin K . Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995; 1(10):1111-8. View

3.
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J . Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57(2):314-9. View

4.
Lengauer C, Kinzler K, Vogelstein B . Genetic instability in colorectal cancers. Nature. 1997; 386(6625):623-7. DOI: 10.1038/386623a0. View

5.
Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L . Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 2008; 68(1):122-31. DOI: 10.1158/0008-5472.CAN-07-1939. View